Early Lyme Disease Alarm Shocks Scientists

Scientist examining samples under a microscope in a laboratory

Researchers at Tufts University have found two blood markers that can flag Lyme disease even before standard tests turn positive — a potential game-changer for the nearly half a million Americans diagnosed each year.

Story Snapshot

Two anti-lipid antibodies — anti-phosphatidic acid and anti-phosphatidylserine — showed up in Lyme patients whose standard tests were still negative, according to a June 2026 Tufts University study.
The anti-phosphatidylserine marker was still elevated months later in patients with persistent symptoms after treatment, suggesting it could track ongoing disease.
Researchers are clear: these findings do not yet support a new clinical test, and larger studies are needed before doctors can use them.
This is at least the fifth distinct wave of Lyme biomarker discoveries since 2019 — none has reached a doctor’s office yet.

Why Standard Lyme Tests Leave Patients in the Dark

Current blood tests for Lyme disease look for antibodies your immune system makes against the bacteria. The problem is that your body takes weeks to build those antibodies. During that window, the test comes back negative — even if you are infected. The Johns Hopkins Lyme Disease Research Center confirms that no single test can definitively confirm or rule out Lyme disease, and that results can stay negative in the early stages. That gap has real consequences. Delayed diagnosis can lead to heart problems, joint damage, and neurological illness.

The standard two-step testing process — an enzyme-linked immunosorbent assay followed by a Western Blot — was designed for reliability in later stages of infection. It was never built for speed. That design flaw has frustrated patients and doctors for decades, and it is exactly the gap the Tufts team is trying to close.

What the Tufts Team Actually Found

The Tufts University School of Medicine study, published June 30, 2026, identified three anti-lipid antibodies in Lyme patients. Two of them — anti-phosphatidic acid and anti-phosphatidylserine — were elevated at the time of diagnosis, even in patients who had not yet tested positive on standard Lyme tests. That is the headline finding. The body appears to react to certain fats disrupted by the Lyme bacteria before it mounts the full antibody response that current tests detect.

The anti-phosphatidylserine finding goes further. Patients who still had symptoms after completing treatment were more likely to show elevated anti-phosphatidylserine levels months later. That matters because post-treatment Lyme disease syndrome — the condition where symptoms linger after antibiotics — has no reliable blood marker today. Doctors currently have no way to measure whether treatment worked. A marker that tracks persistent disease would be a separate breakthrough on top of early detection.

This Is Not the First Time Science Has Said “Almost There”

Here is where honest perspective matters. In 2019, a study published in Frontiers in Cellular and Infection Microbiology used mass spectrometry and protein microarrays to uncover six potential biomarkers for early Lyme detection — and stated plainly that no consistently reliable biomarker for Lyme disease existed at the time. In 2023, a Nature study pointed to a protein called VlsE as a robust marker across all stages of infection. In 2024, a bioinformatics study identified three genes — FCGR1B, MPP1, and HSPA6 — as strong candidates using machine learning. None of these has become a clinical test.

The Tufts researchers themselves draw this line clearly. The findings do not yet support a new clinical test, and larger studies are needed to determine how accurately the markers identify infection and predict long-term symptoms. That is not a dismissal of the work — it is scientific honesty. The findings are real. The path from lab discovery to your doctor’s office is long, expensive, and littered with promising ideas that never made it.

The Roadblocks Between Discovery and Your Doctor’s Office

Even if larger trials validate these markers, the road ahead is steep. The Centers for Disease Control and Prevention’s 2022 case definition for Lyme disease still requires two-tier serology, bacterial culture, or nucleic acid testing for confirmatory evidence — anti-lipid antibodies are not on that list. Without a change to official guidelines, most clinicians will not order a new test even if one exists. Institutional inertia in medicine is real, and it moves slowly.

Insurance coverage is another wall. New biomarker tests routinely struggle to get paid for, even when the science is solid. The pattern has played out with cardiac biomarkers, Alzheimer’s markers, and others. A new Lyme test would face the same fight. That means even a validated, Food and Drug Administration-cleared test could sit unused because payers will not cover it — a frustrating but predictable outcome that policymakers should address proactively rather than reactively.

Why This Round of Research Still Deserves Attention

Despite the cautious framing, the Tufts findings stand out for one reason the earlier studies lacked: the anti-phosphatidylserine marker’s potential to track disease after treatment. That is a different and arguably more urgent problem than early detection alone. Hundreds of thousands of patients are told they are cured but still feel sick, with no objective measure to validate their experience or guide further care. A blood marker that reflects ongoing disease activity — not just past infection — would change the conversation between patients and doctors in a meaningful way. That is worth watching closely as the next round of studies gets underway.